Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of MORAb-202 in Solid Tumors
jRCT2080223761Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of farletuzumab ecteribulin in Nonhematologic neoplasms, ovarian cancer, fallopian tube cancer (PFTC) and 4 more (5 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Safety and tolerability of MORAb-202. Started Dec 2017; status: completed.
02
Drugs
farletuzumab ecteribulin
03
Conditions
Nonhematologic neoplasmsovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2080223761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223761.